In a New Yorker article about how evolutionary psychology findings are usually based on surveys of undergraduates, Anthony Gottlieb wrote, “American college kids, whatever their charms, are a laughable proxy for Homo sapiens.”
How Diversity in Clinical Trials Improves Disease Research
Some connections between ethnicity and disease are relatively straightforward. Tay-Sachs disease, for example, is a rare genetic disorder caused by mutations in a gene located on chromosome 15. The condition occurs more frequently among individuals of Ashkenazi Jewish descent than in many other populations. Because people inherit two copies of the gene, a child has a 25% chance of developing the disease if both parents carry the mutation.
However, most diseases result from a combination of genetic and lifestyle factors rather than a single gene. Understanding why certain conditions affect specific populations at higher rates can provide valuable insights for researchers and healthcare professionals. This is another reason why diversity in clinical trials remains essential for advancing medical knowledge.
Diversity in Clinical Trials and NAFLD Research
Nonalcoholic fatty liver disease (NAFLD) affects nearly one-quarter of the global population. The condition develops when excess fat accumulates in the liver without excessive alcohol consumption. In some patients, NAFLD progresses to inflammation, fibrosis, and eventually cirrhosis, which can cause permanent liver damage.
A more severe form of the disease, known as nonalcoholic steatohepatitis (NASH), combines excess liver fat with inflammation and fibrosis. Over time, these changes can significantly reduce liver function and increase the risk of serious health complications.
Estimating the prevalence of NASH remains challenging. Physicians often diagnose the condition by excluding other liver diseases, and diagnostic approaches can vary between healthcare systems. Although liver biopsy remains the gold standard, researchers also use advanced imaging technologies such as magnetic resonance imaging (MRI) to estimate disease prevalence across larger populations.
Thanks to increased diversity in clinical trials and observational studies, researchers now have a better understanding of how NAFLD affects different ethnic groups. One study found that NAFLD prevalence was highest among Mexican Americans at 21.2 percent, followed by non-Hispanic whites at 12.5 percent and non-Hispanic Blacks at 11.6 percent.
Researchers have also linked NAFLD and NASH to obesity, type 2 diabetes, dyslipidemia, and hypertension. However, experts caution against oversimplifying these relationships. While lifestyle factors play an important role, biological and genetic influences may also contribute to disease risk.
According to clinical researchers studying NAFLD and NASH, not every patient fits a typical profile. Some individuals who appear lean and physically active may still develop liver disease. This complexity highlights the importance of studying diverse populations rather than relying on assumptions based on appearance or lifestyle alone.
To better understand these patterns, researchers continue expanding diversity in clinical trials. Broader participant representation allows scientists to identify risk factors, evaluate treatment responses, and improve disease prevention strategies across different populations.
The Future of Diversity in Clinical Trials
Expanding diversity in clinical trials will help researchers better understand how diseases affect people from different backgrounds. More representative study populations can improve diagnostic accuracy, support personalized treatment approaches, and strengthen the reliability of clinical research findings.
As medical science continues to evolve, diversity in clinical trials will remain a critical factor in advancing healthcare innovation. By including participants from a wide range of demographic and ethnic groups, researchers can generate more meaningful data and develop solutions that benefit patients worldwide.